QAPSA: post-marketing surveillance of capsaicin 8% patch for long-term use in patients with peripheral neuropathic pain in France.

Curr Med Res Opin. 2019 Mar;35(3):417-426. doi: 10.1080/03007995.2018.1558850. Epub 2019 Jan 7. Lantéri-Minet M1,2, Perrot S3. Abstract OBJECTIVE: To describe the characteristics of patients treated with the capsaicin 8% patch, prescribing conditions, long-term effects of repeat treatment on pain intensity

Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study.

Lancet. 2018 Nov 24;392(10161):2280-2287. doi: 10.1016/S0140-6736(18)32534-0. Epub 2018 Oct 22. Reuter U1, Goadsby PJ2, Lanteri-Minet M3, Wen S4, Hours-Zesiger P5, Ferrari MD6, Klatt J5. Abstract BACKGROUND: A substantial proportion of patients with migraine does not respond to, or cannot tolerate,